AOD-9604

Plain-English version: AOD-9604 is a small protein fragment ("peptide") that scientists copied from the fat-burning tail end of human growth hormone (hGH). The goal was to keep only the part of growth hormone that mobilizes fat, and leave behind the parts that raise blood sugar or make tissues grow.

"AOD" stands for Advanced Obesity Drug (sometimes written "Anti-Obesity Drug"), reflecting the reason it was created. Structurally, it is a synthetic analog of the C-terminal lipolytic domain of human growth hormone — specifically the hGH 177-191 region with an extra tyrosine attached at the front (chemists write it as Tyr-hGH177-191), giving a 16-amino-acid peptide.^[1] That N-terminal tyrosine was added to improve stability and activity. (Note: many websites, including older versions of this page, cite the region as "176-191" — the primary research papers use 177-191.)

The compound came out of the laboratory of Professor Frank Ng and colleagues, and was developed commercially by the Australian company Metabolic Pharmaceuticals. Their systematic question was simple: which piece of the growth-hormone molecule actually burns fat, and can we use just that piece without the rest of hGH's effects?

The critical innovation of AOD-9604 is what it does not do. Full-length growth hormone stimulates fat breakdown but also raises blood glucose (the "diabetogenic" effect), increases IGF-1 (which drives tissue growth), and can cause fluid retention, joint pain, and carpal tunnel syndrome. In animal work AOD-9604 delivered the fat-metabolizing action without measurably touching insulin sensitivity or IGF-1 — and human trials later confirmed the IGF-1 and glucose safety story held in people too.^[1][4]

The credibility caveat, stated up front: a clean safety profile is not the same as strong efficacy. AOD-9604's obesity program was discontinued around 2007 after weight-loss results proved modest and a longer trial failed its primary endpoint. It never advanced to Phase 3 and is not approved as a drug anywhere.^[6] For the legal picture, see Are Peptides Legal?

Takeaway first: AOD-9604 mimics the fat-burning end of growth hormone. In animal studies it nudges fat cells to release and burn stored fat, and it appears to restore the machinery cells use to burn fat, all without flipping the "grow" and "raise blood sugar" switches that full growth hormone activates. Here is what the verified research actually shows, and where it stops.

1. Stimulating lipolysis — releasing stored fat

"Lipolysis" just means breaking down stored fat (triglycerides) into free fatty acids the body can burn for energy. In obese rodents, AOD-9604 increased the fat-releasing (lipolytic) activity of fat tissue and reduced body-weight gain.^[1] Crucially, it did this without the harm to insulin sensitivity that full-length hGH causes — in obese Zucker rats given oral AOD-9604 at 500 mcg/kg/day for 19 days, body-weight gain fell by more than half (15.8 vs 35.6 g versus controls) with no adverse effect on insulin sensitivity measured by euglycemic clamp.^[1] Evidence level: rats.

2. Increasing fat oxidation and restoring beta-3 receptor expression

Beyond releasing fat, AOD-9604 appears to help the body actually burn it. In obese mice, chronic treatment with hGH or AOD-9604 reduced body weight and fat and restored the suppressed expression of the beta-3 adrenergic receptor (beta3-AR) — a receptor on fat cells tied to fat burning and energy expenditure.^[2] A companion study found AOD-9604 increased fat oxidation and produced weight loss in obese mice comparable to full-length hGH.^[3] Evidence level: mice.

3. The mechanism is subtler than "it activates beta-3 receptors"

A common oversimplification online is that AOD-9604 "works through beta-3 receptors." The actual data are more nuanced. In beta3-AR knockout mice (animals genetically missing the receptor), chronic AOD-9604 failed to reduce weight — yet a single acute dose still raised energy expenditure and fat oxidation.^[2] The researchers concluded its lipolytic action is not mediated directly through beta3-AR, even though it up-regulates beta3-AR expression over time. In other words, AOD-9604 seems to reset the fat-burning machinery rather than simply flipping one receptor on. Evidence level: mechanistic animal work.

4. What it deliberately does NOT do

The design goal was selectivity, and this is the best-verified part of the story. AOD-9604 does not raise IGF-1 and does not impair glucose tolerance — confirmed in both animals and, importantly, in humans.^[1][4] This is why it avoids growth hormone's classic downsides (tissue growth, insulin resistance, fluid retention).

What we do NOT know

There is no fully characterized human receptor target or human pharmacokinetic profile that would let anyone predict a precise dose-response in people. The mechanisms above are real published findings — but the efficacy-relevant ones are almost entirely from rats and mice, and a clear mechanism in animals did not translate into clear weight loss in the human trials (see below).

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. AOD-9604 is unusual among research peptides because it has real human data — so pay close attention to which findings are human and which are animal.

Fat loss (animal evidence: strong; human evidence: modest and ultimately negative)

Claim: reduces body fat by mobilizing and burning stored fat. Mechanism: increased lipolysis and fat oxidation, with restored beta3-AR expression. Population studied: obese Zucker rats and diet-induced obese mice; then obese human adults in Phase 1/2 trials. Effect: in rodents, AOD-9604 cut body-weight gain by over 50% and raised fat oxidation without harming insulin sensitivity.^[1][3] In humans, the best-responding oral dose (~1 mg) produced roughly 1.8-2.0 kg more weight loss than placebo over 12 weeks — real, but small.^[6] Limitation: a subsequent longer (24-week) trial failed its primary weight-loss endpoint, and development was halted around 2007; the compound never reached Phase 3.^[6] The honest bottom line: the animal fat-loss data are impressive, but the human fat-loss data did not clear the bar a drug needs to clear.

No blood-sugar or IGF-1 penalty (human evidence: strong)

Claim: delivers fat effects without growth hormone's metabolic downsides. Mechanism: the fragment lacks the signaling that raises IGF-1 and impairs glucose handling. Population studied: a pooled analysis of six randomized, double-blind, placebo-controlled human trials. Effect: AOD-9604 had no effect on serum IGF-1, no adverse effect on glucose tolerance (measured by oral glucose tolerance test), and produced no anti-AOD9604 antibodies.^[4] Limitation: this is a safety finding, not an efficacy one — it tells you what AOD-9604 avoids, not how much fat it removes.

Cartilage and joint support (animal only)

Claim: may support cartilage in osteoarthritis. Mechanism: proposed anti-degenerative effect on joint cartilage, tested alongside hyaluronic acid. Population studied: rabbits in a collagenase-induced knee osteoarthritis model. Effect: intra-articular (into-the-joint) AOD-9604 combined with hyaluronic acid produced significantly lower cartilage-degeneration scores and shorter lameness than either agent alone.^[5] Limitation: this is a rabbit study, not a human one. You will find claims online of a human "Journal of Stem Cells and Regenerative Medicine" cartilage study — that source could not be verified, so treat joint benefits as a preliminary animal signal, not proven human therapy. For related repair-focused peptides, see peptides for joint health.

The honest bottom line on "benefits"

• Animal fat-loss data are genuinely good — consistent weight and fat reduction without insulin-sensitivity harm.
• Human fat-loss data are the weak link — modest effect, a failed longer trial, and discontinued development.^[6]
• The safety story is the standout — across six controlled human trials, tolerability was indistinguishable from placebo.^[4]
• Joint/cartilage use is early-stage animal work, not established.

Read this first: AOD-9604 is not an approved drug, and there is no medically endorsed dose for self-administration. What we can describe are the doses actually used in research. In the human trials, the compound was studied orally, with the best response around 1 mg/day.^[4][6] The subcutaneous 250-500 mcg/day figures circulating in the research-chemical community are conventions extrapolated from that program, not trial-validated injectable doses. We describe them for completeness and harm reduction, not as medical guidance.

Commonly cited research protocols

Experience level	Route	Dose	Frequency	Timing
Starting / conservative	Subcutaneous	250 mcg	Once daily	Morning, fasted
Standard	Subcutaneous	300-500 mcg	Once daily	Morning, fasted
Clinical-trial reference	Oral	1 mg	Once daily	Before meals
Maintenance	Subcutaneous	250 mcg	5 days on / 2 off	Morning, fasted

Note the disconnect: the injectable doses hobbyists use (micrograms) are far lower than the oral dose that showed the best human response (1 milligram = 1,000 mcg). That gap reflects differences in absorption between routes and the fact that injectable protocols were never formally validated in trials.

Why fasted, morning administration?

Most protocols dose AOD-9604 first thing in the morning on an empty stomach. The rationale is mechanistic: insulin — which rises after you eat — suppresses lipolysis (fat release). Dosing in a fasted state, when insulin is low, is thought to avoid working against the peptide's fat-mobilizing action. Practical convention:

• Dose at least 2 hours after your last meal (fasted overnight is easiest).
• Some protocols wait 30-60 minutes after dosing before eating.
• Morning-on-waking is the most practical fasted window, and pairs with fasted cardio in many routines.

Reconstitution math, with a worked example

AOD-9604 ships as a lyophilized (freeze-dried) powder, commonly in 2 mg or 5 mg vials, that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 5 mg vial and add 2 mL of bacteriostatic water. That gives 5 ÷ 2 = 2.5 mg/mL, i.e. 2,500 mcg per mL. To draw a 250 mcg dose: 250 ÷ 2,500 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 500 mcg dose is 0.20 mL, or 20 units.

Vial	BAC water	Concentration	250 mcg	500 mcg
5 mg	2 mL	2.5 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)
5 mg	1 mL	5.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)
2 mg	1 mL	2.0 mg/mL	0.125 mL (12.5 units)	0.25 mL (25 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Cycle length and timing

• Typical cycle: research and hobbyist protocols run 8-12 weeks; clinical trials used 12- and 24-week treatment periods.
• Ramp: some protocols start at 250 mcg and increase to 500 mcg after 2-4 weeks if tolerated. No loading dose or taper is described.
• Realistic timeline: because AOD-9604 works through gradual fat mobilization rather than appetite suppression, changes accumulate slowly — modest shifts by week 4, more visible results by weeks 8-12, always alongside a caloric deficit and exercise.

None of the above is a recommendation to self-administer an unapproved compound — it is a description of how research doses are structured.

Straight talk: AOD-9604 has one of the cleanest safety records in the research-peptide world, and unlike most peptides that claim this, it has the human data to back it up. A pooled analysis of six randomized, double-blind, placebo-controlled trials found tolerability indistinguishable from placebo, with no drug-related serious adverse events and no trial withdrawals attributable to the compound.^[4] That is genuinely reassuring — but "safe" is not the same as "effective," and product quality remains a separate, real hazard with any unregulated research chemical.

Reported side effects

Effect	Frequency	Severity	Notes / management
Injection-site redness / mild irritation	Most common	Mild	Rotate sites; typically resolves within 24-48 hours
Headache	Uncommon	Mild	Usually incidental; hydrate, self-limiting
Mild nausea	Uncommon	Mild	More often with oral use
Fatigue	Uncommon	Mild	Usually settles within the first week
Anti-AOD9604 antibodies	Not detected	—	No antibody formation across pooled trials[4]
Raised blood glucose / hypoglycemia	Not observed	—	No adverse effect on glucose tolerance[4]
Joint pain / carpal tunnel	Not observed	—	Lacks the growth effects of full hGH

Across the pooled human trials, the safety signal was indistinguishable from placebo apart from local injection-site effects, with no related serious adverse events.^[4]

Why AOD-9604 avoids the classic growth-hormone side effects

Full human growth hormone (somatropin) has a well-documented side-effect profile: fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, and IGF-1 elevation (which underlies theoretical cancer concerns from sustained exposure). AOD-9604 was engineered to sidestep these by isolating only the fat-metabolizing fragment.

• No IGF-1 elevation: serum IGF-1 was unchanged across the pooled human trials.^[4]
• No glucose harm: glucose tolerance (OGTT) was unaffected — a key advantage over full hGH.^[4]
• No growth effects on existing tissue: no organ enlargement or carpal-tunnel signal reported.
• The tradeoff: the same selectivity that removes the risks also removes hGH's muscle-building and other systemic effects — AOD-9604 is not anabolic.

Contraindications, pregnancy & special populations

• Pregnancy and breastfeeding: no controlled human pregnancy data exist. Standard advice is to avoid all peptides during pregnancy and breastfeeding.
• Children and adolescents: not studied in pediatric populations; not recommended outside trials.
• Active malignancy: although AOD-9604 does not raise IGF-1 (the driver of most oncology concerns with hGH), the precautionary principle applies — discuss with oncology before any peptide.
• Severe renal or hepatic impairment: not studied; the peptide's elimination pathway is not fully characterized.
• Known allergy or hypersensitivity to the molecule or formulation excipients.

Drug interactions

No well-characterized clinical drug interactions exist for AOD-9604 at research doses, and it does not raise blood glucose. Given its fasted-dosing rationale (insulin suppresses lipolysis), people using insulin or other glucose-lowering drugs should coordinate timing with a clinician, though no clinical hypoglycemia signal has been observed.^[4]

What to do if you experience side effects

• Persistent injection-site reaction beyond 72 hours: rotate sites and review technique (see the injection technique guide).
• Headache or fatigue beyond the first week: reduce dose, and if it persists, discontinue and seek evaluation.
• Allergic reaction (rash, hives, breathing difficulty): discontinue immediately and seek emergency care.
• Unexplained systemic symptoms: because AOD-9604 has such a benign profile, new systemic symptoms warrant a search for another cause. Stop and evaluate.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: AOD-9604 is sold in the US only as a "research chemical," so purity and identity vary widely between suppliers. For a peptide whose own benefit is modest, contamination is arguably a bigger practical risk than the peptide itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

Setting the record straight on "FDA GRAS status"

You will read almost everywhere that AOD-9604 has "FDA GRAS status" (Generally Recognized as Safe as a food ingredient). This claim needs a correction. When we searched the FDA GRAS Notice Inventory for AOD-9604, we found no completed GRAS notice for it. The GRN number frequently cited for AOD-9604 — GRN 530 — is actually a different substance entirely: an extract of Apocynum venetum leaves, notified by a Japanese company.^[8] The "GRAS" positioning appears to trace to a company/author self-determination describing AOD-9604 as a nutraceutical ingredient, published in 2014 — not an FDA-issued "no questions" GRAS letter.^[7]

So the accurate framing is: AOD-9604's "GRAS" label is a self-affirmed, company-claimed food-ingredient status, not an FDA approval and not a verified FDA GRAS notice. And to be clear, GRAS (even when genuine) is a food-ingredient category, not drug approval. AOD-9604 is not an FDA-approved drug.

Legal and regulatory status (2026)

• Not FDA-approved as a drug. AOD-9604 completed Phase 1 and Phase 2/2b human trials for obesity but was discontinued after failing to beat placebo; it never reached Phase 3.^[6]
• No verified FDA GRAS notice. The commonly cited GRN 530 is a different substance; treat "GRAS" as a self-determination, not an FDA action.^[7][8]
• Sold as a research chemical in the US; therapeutic use falls under state and federal compounding rules.
• Sports: as a growth-hormone-derived fragment, athletes should assume anti-doping authorities treat it as prohibited.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight of the 16-amino-acid peptide.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid (shorter shelf life, higher contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Storage

Keep unopened lyophilized vials cold and dark (freezer or refrigerator). Once reconstituted, refrigerate at 2-8°C and use within a few weeks; never freeze a reconstituted solution, and discard anything cloudy or discolored. See the full peptide storage guide, and for the complete legal picture read Are Peptides Legal?

AOD-9604 is usually weighed against a few neighbors. None of these comparisons come from head-to-head human trials — they contrast mechanisms and the available evidence. The single most important context: AOD-9604's own weight-loss trials were modest and ultimately negative, while the GLP-1 drugs below have large, approved efficacy.

Compound	Mechanism	GH / IGF-1 effect?	Weight-loss magnitude	FDA status
AOD-9604	hGH fragment — lipolysis only	No IGF-1 increase	Modest (trials failed primary endpoint)	Not approved; sold as research chemical
Tesamorelin	GHRH analog — stimulates GH release	Yes (raises IGF-1)	Targets visceral fat	FDA-approved drug
Semaglutide	GLP-1 agonist — appetite suppression	No	Large (~15-17% body weight)	FDA-approved drug
Tirzepatide	GLP-1/GIP dual agonist	No	Large (~20%+)	FDA-approved drug
Retatrutide	GLP-1/GIP/glucagon triple agonist	No	Very large (in trials)	Phase 3 trials

The honest positioning: if your goal is significant weight loss, the GLP-1 medications are dramatically more effective. AOD-9604's niche is targeted, gentle fat-metabolism support with an excellent safety profile and no appetite, blood-sugar, or IGF-1 effects — best suited to someone already lean-ish and dialed in on diet and training who wants a low-risk nudge, not a primary weight-loss tool. For the broader picture, see the peptides for weight loss guide.